Reading LUCD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LUCD free→Reading LUCD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LUCD free→QuarterlyIQ Insights · LUCD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
is incorporated herein by reference. The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Other Events. On April 24, 2026, the Company closed on the sale of 18,000,000 shares (the “ Shares ”) of the Company’s common stock, at a price of $1.00 per share, in its previously announced underwritten offering to the public (the “ Offering ”). The net proceeds from the Offering, after deducting the underwriting discount and other estimated expenses of the Offering, are expected to be approximately $16.8 million. The Company intends to use the net proceeds from the Offering for working cap…
Entry Into a Material Definitive Agreement. On April 23, 2026, Lucid Diagnostics Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Canaccord Genuity LLC and BTIG, LLC, as representatives (the “ Representatives ”) of the underwriters named therein (the “ Underwriters ”), for an underwritten offering to the public of shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a public offering price of $1.00 per s…
is incorporated herein by reference. The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
is incorporated herein by reference. The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. Effective September 22, 2025, the board of directors of Lucid Diagnostics Inc. (the “ Company ”) appointed John R. Palumbo as a Class B director of the Company. Mr. Palumbo was designated for appointment by certain of the holders of the Company’s 12% Convertible Secured Promissory Notes Due 2029 (the “ Convertible Notes ”). Under the agreements go…
Other Events. On September 11, 2025, the Company closed on the sale of 28,750,000 shares (the “ Shares ”) of the Company’s common stock, at a price of $1.00 per share, in its previously announced underwritten offering to the public (the “ Offering ”). The Shares include 3,750,000 shares of the Company’s common stock subject to the underwriters’ option, which was exercised in full at the closing. The net proceeds from the Offering, after deducting the underwriting discount and other estimated…
Entry Into a Material Definitive Agreement. On September 10, 2025, Lucid Diagnostics Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Canaccord Genuity LLC and BTIG, LLC, as representatives (the “ Representatives ”) of the underwriters named therein (the “ Underwriters ”), for an underwritten offering to the public of shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a public offering price of $1.00 p…
is incorporated herein by reference. The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Entry Into a Material Definitive Agreement. On May 30, 2025, Lucid Diagnostics Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with Maxim Group LLC, as sales agent (the “ Agent ”), pursuant to which the Company may offer and sell, from time to time through or to the Agent (the “ Offering ”), shares of its common stock (the “ Shares ”). Under the Agreement, the Agent may sell Shares by any method permitted by law and deemed to be an “at the market offering” as defined…
is incorporated herein by reference. The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Changes in Registrant’s Certifying Accountant. On November 1, 2024, CBIZ CPAs P.C. (“ CBIZ CPAs ”) acquired the attest business of Marcum LLP (“ Marcum ”). Accordingly, on April 23, 2025, solely as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of Lucid Diagnostics Inc. (the “ Company ”) and, with the approval of the audit committee of the Company’s board of directors, CBIZ CPAs was engaged as the Company’s independent registered public accou…
Other Events. On April 11, 2025, the Company closed on the sale of 14,375,000 shares (the “ Shares ”) of the Company’s common stock, at a price of $1.20 per share, in its previously announced underwritten offering to the public (the “ Offering ”). The Shares include 1,875,000 shares of the Company’s common stock subject to the underwriters’ option, which was exercised in full at the closing. The net proceeds from the Offering, after deducting the underwriting discount and other estimated expe…
Entry Into a Material Definitive Agreement. On April 9, 2025, Lucid Diagnostics Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Canaccord Genuity LLC, as representative (the “ Representative ”) of the underwriters named therein (the “ Underwriters ”), for an underwritten offering to the public of shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a public offering price of $1.20 per share (the “ Offer…
is incorporated herein by reference. The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.
Other Events. On March 5, 2025, the Company closed on the sale of 13,939,331 shares of its common stock, pursuant to its previously announced offering of shares of common stock at a price of $1.10 per share (the “ Offering ”). The Company estimates that the net proceeds of the Offering, after deducting the estimated placement agent’s fees and other expenses of the Offering, will be approximately $14.5 million. The Company intends to use the net proceeds from the Offering for working capital a…
Other Events. Termination of ATM Prospectus Supplement In November 2022, Lucid Diagnostics Inc. (the “ Company ”) entered into a Controlled Equity Offering℠ Sales Agreement (the “ Sales Agreement ”) with Cantor Fitzgerald & Co. (“ Cantor ”). Pursuant to the Sales Agreement, from time to time, the Company may offer and sell shares of its common stock to or through Cantor, acting as sales agent or principal. Sales of the Company’s common stock by Cantor, if any, under the Sales Agreement may be…
Other Events. On March 4, 2025, Lucid Diagnostics Inc. (the “ Company ”) entered into a placement agency agreement (the “ Placement Agency Agreement ”) with Canaccord Genuity LLC (the “ Placement Agent ”). Under the Placement Agency Agreement, the Placement Agent agreed to act as the placement agent, on a commercially reasonable “best efforts” basis, for a proposed offering by the Company of shares of its common stock (the “ Offering ”). As compensation for such services, the Company agreed t…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.